Literature DB >> 21062993

Akt and autophagy cooperate to promote survival of drug-resistant glioma.

Qi-Wen Fan1, Christine Cheng, Chris Hackett, Morri Feldman, Benjamin T Houseman, Theodore Nicolaides, Daphne Haas-Kogan, C David James, Scott A Oakes, Jayanta Debnath, Kevan M Shokat, William A Weiss.   

Abstract

Although the phosphatidylinositol 3-kinase to Akt to mammalian target of rapamycin (PI3K-Akt-mTOR) pathway promotes survival signaling, inhibitors of PI3K and mTOR induce minimal cell death in PTEN (phosphatase and tensin homolog deleted from chromosome 10) mutant glioma. Here, we show that the dual PI3K-mTOR inhibitor PI-103 induces autophagy in a form of glioma that is resistant to therapy. Inhibitors of autophagosome maturation cooperated with PI-103 to induce apoptosis through the mitochondrial pathway, indicating that the cellular self-digestion process of autophagy acted as a survival signal in this setting. Not all inhibitors of mTOR synergized with inhibitors of autophagy. Rapamycin delivered alone induced autophagy, yet cells survived inhibition of autophagosome maturation because of rapamycin-mediated activation of Akt. In contrast, adenosine 5'-triphosphate-competitive inhibitors of mTOR stimulated autophagy more potently than did rapamycin, with inhibition of mTOR complexes 1 and 2 contributing independently to induction of autophagy. We show that combined inhibition of PI3K and mTOR, which activates autophagy without activating Akt, cooperated with inhibition of autophagy to cause glioma cells to undergo apoptosis. Moreover, the PI3K-mTOR inhibitor NVP-BEZ235, which is in clinical use, synergized with the lysosomotropic inhibitor of autophagy, chloroquine, another agent in clinical use, to induce apoptosis in glioma xenografts in vivo, providing a therapeutic approach potentially translatable to humans.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062993      PMCID: PMC3001107          DOI: 10.1126/scisignal.2001017

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  74 in total

1.  Macroautophagy inhibition sensitizes tamoxifen-resistant breast cancer cells and enhances mitochondrial depolarization.

Authors:  M A Qadir; B Kwok; W H Dragowska; K H To; D Le; M B Bally; Sharon M Gorski
Journal:  Breast Cancer Res Treat       Date:  2008-01-03       Impact factor: 4.872

2.  Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria.

Authors:  H S Günther; N O Schmidt; H S Phillips; D Kemming; S Kharbanda; R Soriano; Z Modrusan; H Meissner; M Westphal; K Lamszus
Journal:  Oncogene       Date:  2007-11-26       Impact factor: 9.867

3.  UVA-induced cell cycle progression is mediated by a disintegrin and metalloprotease/epidermal growth factor receptor/AKT/Cyclin D1 pathways in keratinocytes.

Authors:  Yu-Ying He; Sarah E Council; Li Feng; Colin F Chignell
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

4.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.

Authors:  Sauveur-Michel Maira; Frédéric Stauffer; Josef Brueggen; Pascal Furet; Christian Schnell; Christine Fritsch; Saskia Brachmann; Patrick Chène; Alain De Pover; Kevin Schoemaker; Doriano Fabbro; Daniela Gabriel; Marjo Simonen; Leon Murphy; Peter Finan; William Sellers; Carlos García-Echeverría
Journal:  Mol Cancer Ther       Date:  2008-07-07       Impact factor: 6.261

5.  Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy.

Authors:  Anja Apel; Ingrid Herr; Heinz Schwarz; H Peter Rodemann; Andreas Mayer
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

6.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

Review 7.  Autophagy in the pathogenesis of disease.

Authors:  Beth Levine; Guido Kroemer
Journal:  Cell       Date:  2008-01-11       Impact factor: 41.582

8.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

Review 9.  Autophagic cell death: the story of a misnomer.

Authors:  Guido Kroemer; Beth Levine
Journal:  Nat Rev Mol Cell Biol       Date:  2008-10-30       Impact factor: 94.444

10.  Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents.

Authors:  Michael Degtyarev; Ann De Mazière; Christine Orr; Jie Lin; Brian B Lee; Janet Y Tien; Wei W Prior; Suzanne van Dijk; Hong Wu; Daniel C Gray; David P Davis; Howard M Stern; Lesley J Murray; Klaus P Hoeflich; Judith Klumperman; Lori S Friedman; Kui Lin
Journal:  J Cell Biol       Date:  2008-10-06       Impact factor: 10.539

View more
  155 in total

1.  Harnessing autophagy for adoptive T-cell therapy.

Authors:  Shoba Amarnath; Daniel H Fowler
Journal:  Immunotherapy       Date:  2012-01       Impact factor: 4.196

2.  Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.

Authors:  Qi-Wen Fan; William A Weiss
Journal:  Methods Mol Biol       Date:  2012

3.  Inhibition of lysosome degradation on autophagosome formation and responses to GMI, an immunomodulatory protein from Ganoderma microsporum.

Authors:  I-Lun Hsin; Gwo-Tarng Sheu; Ming-Shiou Jan; Hai-Lun Sun; Tzu-Chin Wu; Ling-Yen Chiu; Ko-Huang Lue; Jiunn-Liang Ko
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

4.  Targeting the VEGF and PDGF signaling pathway in glioblastoma treatment.

Authors:  Alisa Madalina Popescu; Oana Alexandru; Corina Brindusa; Stefana Oana Purcaru; Daniela Elise Tache; Ligia Gabriela Tataranu; Citto Taisescu; Anica Dricu
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 5.  Autophagy inhibitors.

Authors:  Benoit Pasquier
Journal:  Cell Mol Life Sci       Date:  2015-12-11       Impact factor: 9.261

6.  Discovery and structure of a new inhibitor scaffold of the autophagy initiating kinase ULK1.

Authors:  Michael B Lazarus; Kevan M Shokat
Journal:  Bioorg Med Chem       Date:  2015-07-26       Impact factor: 3.641

Review 7.  Deconvoluting the context-dependent role for autophagy in cancer.

Authors:  Eileen White
Journal:  Nat Rev Cancer       Date:  2012-04-26       Impact factor: 60.716

8.  mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

Authors:  Hala Elnakat Thomas; Carol A Mercer; Larissa S Carnevalli; Jongsun Park; Jesper B Andersen; Elizabeth A Conner; Kazuhiro Tanaka; Tomoo Matsutani; Akio Iwanami; Bruce J Aronow; Liu Manway; S Michel Maira; Snorri S Thorgeirsson; Paul S Mischel; George Thomas; Sara C Kozma
Journal:  Sci Transl Med       Date:  2012-04-25       Impact factor: 17.956

9.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Authors:  Supak Yothaisong; Hasaya Dokduang; Anchalee Techasen; Nisana Namwat; Puangrat Yongvanit; Vajarabhongsa Bhudhisawasdi; Anucha Puapairoj; Gregory J Riggins; Watcharin Loilome
Journal:  Tumour Biol       Date:  2013-07-06

Review 10.  Therapeutic targeting of autophagy in disease: biology and pharmacology.

Authors:  Yan Cheng; Xingcong Ren; William N Hait; Jin-Ming Yang
Journal:  Pharmacol Rev       Date:  2013-08-13       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.